Market News & Trends
Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study
Palisade Bio, Inc. recently announced the completion of patient enrollment in its dose optimization study of LB1148. “Achieving our enrollment target in this study is an…
Enterome Announces First Patient Dosed in Phase 1/2 Trial With Third OncoMimics Immunotherapy in Metastatic Colorectal Cancer
Enterome recently announced the first patient was dosed in the Phase 1/2 AUDREY trial evaluating EO4010, the company’s third OncoMimics candidate, for the treatment of patients with….
SciSparc Receives Approval to Conduct Phase 2b Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
SciSparc Ltd. recently announced it has been granted an approval from the Federal Institute for Drugs and Medical Devices in Germany (BfArM) for its Phase…
Urica Therapeutics Announces Topline Data From Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the US
Urica Therapeutics, Inc. recently announced topline data from the Phase 1 clinical trial evaluating dotinurad in healthy volunteers in the US. The randomized, placebo-controlled Phase…
Curia Wins 2023 Frost & Sullivan Customer Value Leadership Award
Curia recently announced it has been awarded a Best Practices Customer Value Leadership Award in the CRDMO industry by Frost & Sullivan. “We are very…
Berkshire Sterile Manufacturing Announces Plans to Expand Lyophilization Capacity
Berkshire Sterile Manufacturing (BSM) expects to double their lyophilization capacity for their fully automated, isolator-based filling line to meet new demand. A second lyophilizer will…
First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
First Wave BioPharma, Inc. recently announced the final patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation…
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
Harpoon Therapeutics, Inc. recently announced the completion of planned patient enrollment in the Phase 1 dose escalation study evaluating the safety, tolerability, and pharmacokinetics of…
Inozyme Pharma Announces Dosing of First Infant With ENPP1 Deficiency in Phase 1b Trial
Inozyme Pharma, Inc. recently announced dosing of the first patient in its ENERGY-1 trial, a Phase 1b clinical trial of INZ-701 in infants with ENPP1 Deficiency.…
Ascendia Pharmaceuticals Develops Novel Nanoemulsion IV Formulation for Clopidogrel That Received IND Approval
Ascendia Pharmaceuticals CEO Jim Huang, PhD, recently announced Ascendia’s patented Emulsol® nanotechnology has been used to develop a novel nanoemulsion IV formulation for….
MoonLake Immunotherapeutics Achieves Landmark Milestone With Positive Phase 2 Results for Nanobody Sonelokimab in Hidradenitis Suppurativa
MoonLake Immunotherapeutics recently announced positive top-line results from its global Phase 2 MIRA trial evaluating the efficacy and safety of the Nanobody sonelokimab in patients with moderate-to-severe….
Larkspur Biosciences Announces First-in-Class Program Targeting Novel B Cell Checkpoint
Larkspur Biosciences recently reported one of their lead programs is a first-in-class B cell checkpoint, TIM-1. This announcement follows the publication by Larkspur co-founder Vijay…
Clene Announces Publication of Phase 2 CNM-Au8 Clinical Data for the Treatment of ALS
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc. recently announced The Lancet’s journal eClinicalMedicine has published combined detailed analyses of the Phase 2…
Ocean Biomedical Announces US Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma) & Metastatic Melanoma
Patent broadens protection around Ocean Biomedical’s first-in-class anti-CHi3L1 antibody to include new bispecific approaches targeting immune checkpoints, with potential application in….
XOMA Acquires Royalty & Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) & Phase 2 Oncology Asset
XOMA Corporation recently announced it has acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol, an oral therapeutic for Niemann-Pick…
ASLAN Pharmaceuticals Enters Strategic Licensing Deal With Zenyaku Kogyo for the Development & Commercialization of Eblasakimab
ASLAN Pharmaceuticals and Zenyaku Kogyo Co., Ltd., a subsidiary of privately held Zenyaku Holdings Co., Ltd. recently announced a strategic licensing agreement granting Zenyaku exclusive…
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
Eli Lilly and Company and DICE Therapeutics, Inc. recently announced a definitive agreement for Lilly to acquire DICE, a biopharmaceutical company that leverages its proprietary….
Spaulding Clinical Expands Services to Include ADME Clinical Trials
Spaulding Clinical recently announced it is expanding its services to include ADME (absorption, distribution, metabolism, and excretion) clinical trials. This strategic addition further solidifies Spaulding…
Lubrizol Licenses Award-Winning Apisolex™ Excipient to Welton Pharma to Develop a Novel Cancer Therapeutic
The Lubrizol Corporation recently announced the licensing of its novel excipient polymer technology, Apisolex™ excipient, to Welton Pharma (Welton). The license allows….
SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement With GSK
SCYNEXIS, Inc. recently announced the achievement of a $25-million performance-based development milestone under its exclusive license agreement with GSK for….
